Global Lung Stents Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• January 2020, the U.S. FDA approved a 3D-printed airway stent designed to fit a patient’s airway. Conducted by the Cleveland Clinic, the study estimated that around 30,000 stents would be implanted in the U.S. by the end of 2020, indicating a significant potential demand for lung stents in the near future.
• June 2018, Taewoong Medical (South Korea) partnered with Cook Medical (US) to distribute Taewoong's product portfolio in the US market.
• May 2018, Merit Medical Systems, Inc. (US) entered into a worldwide distribution agreement with NinePoint Medical, Inc. (US) to market Merit's gastrointestinal and pulmonary medical devices.
• July 2015, Micro-Tech (Nanjing) Co., Ltd. established a wholly-owned subsidiary in the US, Micro-Tech USA, Inc.

In this report, the Lung Stents Market has been segmented by Product, Material, Product Type, Procedure, End Users and Geography.

Lung Stents Market, Segmentation by Product

The Lung Stents Market has been segmented by Product into Self-Expandable Stents , Non-Expandable Stents and Balloon-Expandable Stents.

Self-Expandable Stents

Self-Expandable Stents dominate the lung stents market, accounting for approximately 56% of global revenue in 2022. These stents offer flexibility and adaptability to airway anatomy, which makes them suitable for treating both benign and malignant airway obstructions. Their ease of placement and removal, combined with improved patient comfort, supports their widespread adoption in clinical practice.

Non-Expandable Stents

Non-Expandable Stents contribute to around 23% of the lung stents market share. These stents are typically used in specialized cases where rigid support is necessary, providing durable and long-term patency in complex airway obstructions. While less commonly used than other types, they are essential in certain clinical scenarios, ensuring versatility in treatment options.

Balloon-Expandable Stents

Balloon-Expandable Stents hold an estimated 21% share in the lung stents market in 2022. Their precision deployment and ability to achieve high radial force make them suitable for managing localized obstructions. These stents are particularly beneficial in cases requiring controlled expansion, offering targeted relief and reducing the risk of migration.

Lung Stents Market, Segmentation by Material

The Lung Stents Market has been segmented by Material into Metal Lung Stents , Silicone Lung Stents and Hybrid Lung Stents.

Metal Lung Stents

Metal Lung Stents dominate the lung stents market, capturing approximately 49% of global revenue in 2022. Known for their durability and radial strength, these stents provide long-term airway patency, particularly in malignant obstructions. Their biocompatibility and minimal tissue reaction contribute to their widespread use in managing complex airway conditions.

Silicone Lung Stents

Silicone Lung Stents hold an estimated 36% share in the lung stents market. Their smooth surface reduces mucus adherence, and their removability makes them ideal for benign airway conditions. Silicone stents are often preferred when long-term placement is unnecessary, offering flexibility and ease of customization to patient anatomy.

Hybrid Lung Stents

Hybrid Lung Stents account for around 15% of the lung stents market. Combining features of both metal and silicone stents, these products provide the advantages of strength, flexibility, and reduced migration. Hybrid stents are increasingly used in challenging cases, offering a tailored approach to complex airway management.

Lung Stents Market, Segmentation by Product Type

The Lung Stents Market has been segmented by Product Type into Tracheal Stents, Bronchial Stents, and Others.

Tracheal Stents

Tracheal Stents dominate the lung stents market, accounting for approximately 52% of global revenue in 2022. These stents are widely used to manage tracheal obstructions caused by tumors or strictures. Their durability and flexibility make them a preferred option for maintaining airway patency in critical cases. The ability to effectively manage malignant and benign airway conditions further reinforces their market position.

Bronchial Stents

Bronchial Stents hold an estimated 34% share of the lung stents market. Designed to treat bronchial obstructions, these stents offer targeted support for airway narrowing due to various causes. Their biocompatibility and ability to adapt to the anatomy of the bronchial tree make them essential in comprehensive lung stent procedures.

Others

The "Others" category, which includes specialized lung stents for complex airway scenarios, contributes to around 14% of the global lung stents market revenue. These stents are used in highly specialized cases and in innovative research settings, ensuring access to customized airway management solutions. Although their share is smaller, they play a crucial role in addressing unique patient needs.

Lung Stents Market, Segmentation by Procedure

The Lung Stents Market has been segmented by Procedure into Bronchoscopy and Laryngoscopy.

Bronchoscopy

Bronchoscopy dominates the lung stents market, capturing approximately 67% of the global revenue share in 2022. This minimally invasive procedure enables precise placement of lung stents to manage airway obstructions. Its advantages include real-time visualization, reduced patient recovery time, and high success rates, making it the preferred approach for lung stent deployment in both benign and malignant conditions.

Laryngoscopy

Laryngoscopy accounts for approximately 33% of the global lung stents market revenue. This procedure is essential in managing laryngeal obstructions and provides direct access to the upper airway. Its precision and effectiveness in treating laryngeal stenosis or other obstructions make it a crucial component of comprehensive airway management, especially in complex cases.

Lung Stents Market, Segmentation by End Users

The Lung Stents Market has been segmented by End Users into Hospitals , Ambulatory Surgery Centers and Others.

Hospitals

Hospitals are the primary end users in the lung stents market, contributing to approximately 59% of global revenue in 2022. Equipped with advanced diagnostic and therapeutic facilities, hospitals provide comprehensive care for patients requiring lung stent placement. The presence of skilled medical professionals and specialized pulmonary departments enhances the adoption of lung stents in this segment.

Ambulatory Surgery Centers

Ambulatory Surgery Centers (ASCs) account for around 28% of the global lung stents market revenue. These centers offer efficient and cost-effective settings for minimally invasive lung stent procedures. The growing demand for outpatient treatments, combined with shorter recovery times and reduced hospital stays, drives the increasing adoption of lung stents in ASCs.

Others

The "Others" category, including specialty clinics and research institutions, holds an estimated 13% share of the global lung stents market. These facilities contribute to the market by offering specialized care for complex airway cases and supporting clinical research on innovative lung stent technologies. Their role in advancing airway management solutions adds valuable diversity to the market.

Lung Stents Market, Segmentation by Geography

In this report, the Lung Stents Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Lung Stents Market Share (%), by Geographical Region

North America

North America leads the lung stents market, accounting for approximately 41% of global revenue in 2022. Factors driving growth include a high prevalence of lung diseases, advanced healthcare infrastructure, and strong presence of leading market players. Significant investments in research and development and the adoption of minimally invasive procedures further strengthen the market in this region.

Europe

Europe contributes to around 27% of the global lung stents market. The region’s growth is supported by a rising incidence of airway disorders, expanding healthcare expenditure, and increasing adoption of lung stent technologies. Regulatory support and reimbursement frameworks also promote wider market penetration.

Asia Pacific

Asia Pacific holds an estimated 21% share of the lung stents market in 2022. Rapidly improving healthcare infrastructure, rising awareness of airway treatments, and increasing cases of chronic respiratory diseases drive the region’s growth. Countries such as China and India offer significant expansion opportunities due to large patient populations and growing healthcare investments.

Middle East and Africa

Middle East and Africa contribute to approximately 6% of the global lung stents market. Growth in this region is primarily driven by improvements in healthcare access and a rising burden of airway diseases. Increased collaboration between healthcare providers and global market leaders is enhancing market presence.

Latin America

Latin America accounts for around 5% of the global lung stents market. Rising prevalence of respiratory diseases, combined with improving medical infrastructure and growing awareness of minimally invasive treatments, support market growth. Increased healthcare investments and expanding access to advanced airway management solutions further drive the region’s market potential.

This report provides an in depth analysis of various factors that impact the dynamics of Global Lung Stents Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers

• Increasing COPD prevalence
• Aging population growth
• Technological advancements surge
• Rising healthcare expenditure

• Growing smoking rates: The rising prevalence of smoking globally continues to be a significant contributor to respiratory ailments, including chronic obstructive pulmonary disease (COPD) and lung cancer. Despite widespread awareness campaigns and efforts to curb tobacco consumption, smoking rates have shown stubborn resilience, especially in certain regions where cultural factors or limited access to cessation resources perpetuate the habit. This persistent smoking trend not only poses a grave public health challenge but also fuels the demand for medical interventions to address the resulting respiratory conditions. As a consequence, the global market for lung stents, which are used in the treatment of conditions like COPD and lung cancer, is experiencing notable growth. This growth is driven not only by the increasing incidence of respiratory diseases but also by advancements in stent technology, enabling more effective and minimally invasive treatments for patients worldwide.

  The global lung stents market is witnessing significant expansion, propelled by factors such as the aging population, the growing prevalence of respiratory disorders, and advancements in medical technology. Lung stents play a crucial role in managing various respiratory conditions, including airway obstruction caused by tumors, inflammation, or structural abnormalities. As healthcare systems strive to improve patient outcomes and reduce the burden of chronic respiratory diseases, the demand for innovative medical devices like lung stents continues to rise. Additionally, increasing investments in healthcare infrastructure, particularly in developing economies, further contribute to the growth of the lung stents market by expanding access to advanced medical treatments. Overall, with the convergence of demographic trends, technological advancements, and healthcare investments, the global lung stents market is poised for sustained growth in the coming years.

Restraints

• High treatment costs
• Limited product awareness
• Stringent regulatory policies
• Complications post-procedure risks

• Insufficient reimbursement schemes: Insufficient reimbursement schemes pose a significant challenge to the growth of the global lung stents market. Lung stents are often used in the treatment of various respiratory conditions, such as chronic obstructive pulmonary disease (COPD) and lung cancer. However, the high cost of these devices combined with inadequate reimbursement policies in many regions hampers their widespread adoption. Healthcare providers may be hesitant to prescribe lung stents if patients cannot afford them or if reimbursement rates are too low, leading to delays in treatment and suboptimal patient outcomes.

  The lack of standardized reimbursement schemes across different countries adds another layer of complexity to the market. Variations in reimbursement policies and rates can create barriers to market entry for companies looking to expand their presence globally. To address these challenges, stakeholders in the lung stents market, including manufacturers, policymakers, and healthcare providers, need to collaborate to develop more equitable reimbursement strategies that ensure patients have access to these life-saving devices without undue financial burden. Additionally, efforts to streamline reimbursement processes and increase transparency can help drive market growth and improve patient access to essential respiratory care.

Opportunities

• Emerging markets potential
• Innovation in materials
• Growing telehealth adoption
• Expanding geriatric care

• Increasing clinical trials: The global lung stents market has been witnessing a notable surge in clinical trials, driven by advancements in medical technology and a growing demand for innovative solutions in respiratory care. Lung stents, which are used to treat various respiratory conditions such as chronic obstructive pulmonary disease (COPD), lung cancer, and bronchial strictures, are undergoing extensive research and development to enhance their efficacy and safety profiles. These clinical trials encompass a spectrum of approaches, including evaluating new materials for stent fabrication, exploring minimally invasive insertion techniques, and assessing long-term patient outcomes. With the rising prevalence of respiratory disorders worldwide and an aging population, there is a pressing need to expand the evidence base for lung stent interventions through rigorous clinical investigation, paving the way for improved therapeutic options and better patient care.

  The increasing clinical trials in the global lung stents market are fostering collaborations among healthcare institutions, medical device manufacturers, and research organizations to accelerate innovation and bring novel solutions to the forefront. This collaborative effort aims to address unmet clinical needs and overcome existing challenges in lung stent therapy, such as stent migration, tissue ingrowth, and stent-related complications. By leveraging multidisciplinary expertise and leveraging technological advancements such as advanced imaging modalities and biomaterial engineering, researchers are poised to develop next-generation lung stents that offer superior performance, durability, and biocompatibility. As these clinical trials progress and yield promising results, they are expected to drive the adoption of lung stent technologies globally, ultimately improving the quality of life for patients suffering from respiratory diseases.

Key players in Global Lung Stents Market include:

• Boston Scientific
• C.R. Bard
• Taewoong Medical
• Micro-Tech (Nanjing)
• Teleflex
• Merit Medical Systems
• Cook Group
• Novatech Sa
• Endo-Flex
• M.I. Tech
• Efer Endoscopy
• Fuji Systems

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis